Cover Image
市場調查報告書

膀胱癌:開發中產品分析

Bladder Cancer - Pipeline Review, H2 2016

出版商 Global Markets Direct 商品編碼 232863
出版日期 內容資訊 英文 742 Pages
訂單完成後即時交付
價格
Back to Top
膀胱癌:開發中產品分析 Bladder Cancer - Pipeline Review, H2 2016
出版日期: 2016年11月09日 內容資訊: 英文 742 Pages
簡介

本報告提供膀胱癌的治療藥開發情形調查分析,提供您開發中產品概要,臨床實驗的各階段產品概要,主要企業簡介,藥物簡介,開發中產品的最新趨勢,最新消息和新聞稿等相關的系統性資訊。

簡介

膀胱癌概要

治療藥的開發

膀胱癌:企業開發中的治療藥

膀胱癌:大學/機關研究中的治療藥

膀胱癌:開發中產品概況

膀胱癌:企業開發中的產品

膀胱癌:大學/機關研究中的產品

膀胱癌的治療藥的開發企業

膀胱癌:治療藥的評估

藥物簡介

膀胱癌:最近的開發平台趨勢

膀胱癌:暫停中的計劃

膀胱癌:開發中止的產品

膀胱癌:產品開發的里程碑

附錄

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: GMDHC8622IDB

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Bladder Cancer - Pipeline Review, H2 2016, provides an overview of the Bladder Cancer (Oncology) pipeline landscape.

Bladder cancer occurs in tissues of the urinary bladder. Symptoms include blood or blood clots in the urine, frequent urination, lower back pain on one side of the body and burning during urination. Risk factors for bladder cancer include smoking, exposure to substances such as rubber, certain dyes and textiles, paint, and hairdressing supplies, diet rich in fried meats and fat, old age, sex and color, certain parasitic infections. Treatment of bladder cancer includes chemotherapy, surgery, biological therapy and radiation therapy.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Bladder Cancer - Pipeline Review, H2 2016, provides comprehensive information on the therapeutics under development for Bladder Cancer (Oncology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Bladder Cancer (Oncology) pipeline guide also reviews of key players involved in therapeutic development for Bladder Cancer and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical and Discovery stages are 1, 9, 44, 35, 2, 56 and 12 respectively. Similarly, the Universities portfolio in Phase II, Phase I, Preclinical and Discovery stages comprises 3, 1, 12 and 2 molecules, respectively.Bladder Cancer.

Bladder Cancer (Oncology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

  • The pipeline guide provides a snapshot of the global therapeutic landscape of Bladder Cancer (Oncology).
  • The pipeline guide reviews pipeline therapeutics for Bladder Cancer (Oncology) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Bladder Cancer (Oncology) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Bladder Cancer (Oncology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Bladder Cancer (Oncology)

Reasons to buy

  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Bladder Cancer (Oncology).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Bladder Cancer (Oncology) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Table of Contents

  • Table of Contents
  • Introduction
  • Bladder Cancer Overview
  • Therapeutics Development
  • Bladder Cancer - Therapeutics under Development by Companies
  • Bladder Cancer - Therapeutics under Investigation by Universities/Institutes
  • Bladder Cancer - Pipeline Products Glance
  • Bladder Cancer - Products under Development by Companies
  • Bladder Cancer - Products under Investigation by Universities/Institutes
  • Bladder Cancer - Companies Involved in Therapeutics Development
  • Bladder Cancer - Therapeutics Assessment
  • Drug Profiles
  • Bladder Cancer - Dormant Projects
  • Bladder Cancer - Discontinued Products
  • Bladder Cancer - Product Development Milestones
  • Appendix

List of Tables

  • Number of Products under Development for Bladder Cancer, H2 2016
  • Number of Products under Development for Bladder Cancer - Comparative Analysis, H2 2016
  • Number of Products under Development by Companies, H2 2016
  • Number of Products under Development by Companies, H2 2016 (Contd..1)
  • Number of Products under Development by Companies, H2 2016 (Contd..2)
  • Number of Products under Development by Companies, H2 2016 (Contd..3)
  • Number of Products under Development by Companies, H2 2016 (Contd..4)
  • Number of Products under Development by Companies, H2 2016 (Contd..5)
  • Number of Products under Development by Companies, H2 2016 (Contd..6)
  • Number of Products under Development by Companies, H2 2016 (Contd..7)
  • Number of Products under Investigation by Universities/Institutes, H2 2016
  • Comparative Analysis by Late Stage Development, H2 2016
  • Comparative Analysis by Clinical Stage Development, H2 2016
  • Comparative Analysis by Early Stage Development, H2 2016
  • Products under Development by Companies, H2 2016
  • Products under Development by Companies, H2 2016 (Contd..1)
  • Products under Development by Companies, H2 2016 (Contd..2)
  • Products under Development by Companies, H2 2016 (Contd..3)
  • Products under Development by Companies, H2 2016 (Contd..4)
  • Products under Development by Companies, H2 2016 (Contd..5)
  • Products under Development by Companies, H2 2016 (Contd..6)
  • Products under Development by Companies, H2 2016 (Contd..7)
  • Products under Development by Companies, H2 2016 (Contd..8)
  • Products under Development by Companies, H2 2016 (Contd..9)
  • Products under Development by Companies, H2 2016 (Contd..10)
  • Products under Investigation by Universities/Institutes, H2 2016
  • Bladder Cancer - Pipeline by 4SC AG, H2 2016
  • Bladder Cancer - Pipeline by Adaptimmune Therapeutics Plc, H2 2016
  • Bladder Cancer - Pipeline by ADC Therapeutics SA, H2 2016
  • Bladder Cancer - Pipeline by Agenus Inc, H2 2016
  • Bladder Cancer - Pipeline by Altor BioScience Corporation, H2 2016
  • Bladder Cancer - Pipeline by AndroScience Corporation, H2 2016
  • Bladder Cancer - Pipeline by APIM Therapeutics AS, H2 2016
  • Bladder Cancer - Pipeline by Arno Therapeutics, Inc., H2 2016
  • Bladder Cancer - Pipeline by Astellas Pharma Inc., H2 2016
  • Bladder Cancer - Pipeline by Astex Pharmaceuticals Inc, H2 2016
  • Bladder Cancer - Pipeline by Aura Biosciences, Inc., H2 2016
  • Bladder Cancer - Pipeline by AVEO Pharmaceuticals, Inc., H2 2016
  • Bladder Cancer - Pipeline by Azaya Therapeutics, Inc., H2 2016
  • Bladder Cancer - Pipeline by Bavarian Nordic A/S, H2 2016
  • Bladder Cancer - Pipeline by Bayer AG, H2 2016
  • Bladder Cancer - Pipeline by BioCancell Ltd, H2 2016
  • Bladder Cancer - Pipeline by Biomics Biotechnologies Co., Ltd., H2 2016
  • Bladder Cancer - Pipeline by Bioncotech Therapeutics SL, H2 2016
  • Bladder Cancer - Pipeline by Biotest AG, H2 2016
  • Bladder Cancer - Pipeline by Boehringer Ingelheim GmbH, H2 2016
  • Bladder Cancer - Pipeline by Bristol-Myers Squibb Company, H2 2016
  • Bladder Cancer - Pipeline by Celgene Corporation, H2 2016
  • Bladder Cancer - Pipeline by Cellceutix Corporation, H2 2016
  • Bladder Cancer - Pipeline by Celldex Therapeutics, Inc., H2 2016
  • Bladder Cancer - Pipeline by Celprogen, Inc., H2 2016
  • Bladder Cancer - Pipeline by Celsion Corporation, H2 2016
  • Bladder Cancer - Pipeline by Codagenix, Inc., H2 2016
  • Bladder Cancer - Pipeline by Cold Genesys, Inc., H2 2016
  • Bladder Cancer - Pipeline by Corvus Pharmaceuticals Inc, H2 2016
  • Bladder Cancer - Pipeline by CytomX Therapeutics, Inc., H2 2016
  • Bladder Cancer - Pipeline by DormaTarg, Inc., H2 2016
  • Bladder Cancer - Pipeline by Eisai Co., Ltd., H2 2016
  • Bladder Cancer - Pipeline by Eleven Biotherapeutics Inc., H2 2016
  • Bladder Cancer - Pipeline by Eli Lilly and Company, H2 2016
  • Bladder Cancer - Pipeline by Elsalys Biotech SAS, H2 2016
  • Bladder Cancer - Pipeline by enGene, Inc, H2 2016
  • ancer - Pipeline by Esperance Pharmaceuticals, Inc., H2 2016
  • Bladder Cancer - Pipeline by F. Hoffmann-La Roche Ltd., H2 2016
  • Bladder Cancer - Pipeline by Five Prime Therapeutics, Inc., H2 2016
  • Bladder Cancer - Pipeline by Gene Signal International SA, H2 2016
  • Bladder Cancer - Pipeline by Genmab A/S, H2 2016
  • Bladder Cancer - Pipeline by GlaxoSmithKline Plc, H2 2016
  • Bladder Cancer - Pipeline by H3 Biomedicine Inc., H2 2016
  • Bladder Cancer - Pipeline by Hamlet Pharma AB, H2 2016
  • Bladder Cancer - Pipeline by Heat Biologics, Inc., H2 2016
  • Bladder Cancer - Pipeline by HEC Pharm Co., Ltd., H2 2016
  • Bladder Cancer - Pipeline by Hutchison MediPharma Limited, H2 2016
  • Bladder Cancer - Pipeline by Idera Pharmaceuticals, Inc., H2 2016
  • Bladder Cancer - Pipeline by ImmuNext, Inc., H2 2016
  • Bladder Cancer - Pipeline by Immunocore Limited, H2 2016
  • Bladder Cancer - Pipeline by Immunomedics, Inc., H2 2016
  • Bladder Cancer - Pipeline by Immupharma Plc, H2 2016
  • Bladder Cancer - Pipeline by InteRNA Technologies B.V., H2 2016
  • Bladder Cancer - Pipeline by Johnson & Johnson, H2 2016
  • Bladder Cancer - Pipeline by LipoMedix Pharmaceutical Inc., H2 2016
  • Bladder Cancer - Pipeline by MacroGenics, Inc., H2 2016
  • Bladder Cancer - Pipeline by MaxiVAX SA, H2 2016
  • Bladder Cancer - Pipeline by Meabco A/S, H2 2016
  • Bladder Cancer - Pipeline by Medicenna Therapeutics, Inc., H2 2016
  • Bladder Cancer - Pipeline by MedImmune LLC, H2 2016
  • Bladder Cancer - Pipeline by Merck & Co., Inc., H2 2016
  • Bladder Cancer - Pipeline by Merck KGaA, H2 2016
  • Bladder Cancer - Pipeline by Mirati Therapeutics Inc., H2 2016
  • Bladder Cancer - Pipeline by Mirna Therapeutics, Inc., H2 2016
  • Bladder Cancer - Pipeline by Miyarisan Pharmaceutical Company, Ltd, H2 2016
  • Bladder Cancer - Pipeline by Moleculin Biotech Inc, H2 2016
  • Bladder Cancer - Pipeline by NanoCarrier Co., Ltd., H2 2016
  • Bladder Cancer - Pipeline by Nektar Therapeutics, H2 2016
  • Bladder Cancer - Pipeline by NuCana BioMed Limited, H2 2016
  • Bladder Cancer - Pipeline by Omeros Corporation, H2 2016
  • Bladder Cancer - Pipeline by Oncogenex Pharmaceuticals, Inc., H2 2016
  • Bladder Cancer - Pipeline by Oncolytics Biotech Inc., H2 2016
  • Bladder Cancer - Pipeline by OncoTherapy Science, Inc., H2 2016
  • Bladder Cancer - Pipeline by Ono Pharmaceutical Co., Ltd., H2 2016
  • Bladder Cancer - Pipeline by Optimum Therapeutics, LLC, H2 2016
  • Bladder Cancer - Pipeline by Pfizer Inc., H2 2016
  • Bladder Cancer - Pipeline by Pharma Mar, S.A., H2 2016
  • Bladder Cancer - Pipeline by Philogen S.p.A., H2 2016
  • Bladder Cancer - Pipeline by Plexxikon Inc., H2 2016
  • Bladder Cancer - Pipeline by Polaris Pharmaceuticals, Inc., H2 2016
  • Bladder Cancer - Pipeline by Provectus Biopharmaceuticals, Inc., H2 2016
  • Bladder Cancer - Pipeline by PsiOxus Therapeutics Limited, H2 2016
  • Bladder Cancer - Pipeline by Rexahn Pharmaceuticals, Inc., H2 2016
  • Bladder Cancer - Pipeline by Rodos BioTarget GmbH, H2 2016
  • Bladder Cancer - Pipeline by Sanofi, H2 2016
  • Bladder Cancer - Pipeline by Savoy Pharmaceuticals, Inc., H2 2016
  • Bladder Cancer - Pipeline by Serometrix, LLC, H2 2016
  • Bladder Cancer - Pipeline by Shionogi & Co., Ltd., H2 2016
  • Bladder Cancer - Pipeline by Sillajen Biotherapeutics, H2 2016
  • Bladder Cancer - Pipeline by Sorrento Therapeutics Inc, H2 2016
  • Bladder Cancer - Pipeline by Spectrum Pharmaceuticals, Inc., H2 2016
  • Bladder Cancer - Pipeline by Stemline Therapeutics, Inc., H2 2016
  • Bladder Cancer - Pipeline by Sun Pharma Advanced Research Co Ltd, H2 2016
  • Bladder Cancer - Pipeline by Synovo GmbH, H2 2016
  • Bladder Cancer - Pipeline by Taiwan Liposome Company, Ltd., H2 2016
  • Bladder Cancer - Pipeline by Tara Immuno-Oncology Therapeutics LLC, H2 2016
  • Bladder Cancer - Pipeline by Taris Biomedical LLC, H2 2016
  • Bladder Cancer - Pipeline by Telormedix SA, H2 2016
  • Bladder Cancer - Pipeline by TesoRx Pharma LLC, H2 2016
  • Bladder Cancer - Pipeline by Theravectys SA, H2 2016
  • Bladder Cancer - Pipeline by Theryte Limited, H2 2016
  • Bladder Cancer - Pipeline by Transgene SA, H2 2016
  • Bladder Cancer - Pipeline by UroGen Pharmaceuticals, Ltd., H2 2016
  • Bladder Cancer - Pipeline by Vakzine Projekt Management GmbH, H2 2016
  • Bladder Cancer - Pipeline by Vault Pharma Inc., H2 2016
  • Bladder Cancer - Pipeline by Vaxeal Holding SA, H2 2016
  • Bladder Cancer - Pipeline by Vaxiion Therapeutics, Inc., H2 2016
  • Bladder Cancer - Pipeline by Viralytics Ltd., H2 2016
  • Assessment by Monotherapy Products, H2 2016
  • Assessment by Combination Products, H2 2016
  • Number of Products by Stage and Target, H2 2016
  • Number of Products by Stage and Mechanism of Action, H2 2016
  • Number of Products by Stage and Route of Administration, H2 2016
  • Number of Products by Stage and Molecule Type, H2 2016
  • Bladder Cancer - Dormant Projects, H2 2016
  • Bladder Cancer - Dormant Projects (Contd..1), H2 2016
  • Bladder Cancer - Dormant Projects (Contd..2), H2 2016
  • Bladder Cancer - Dormant Projects (Contd..3), H2 2016
  • Bladder Cancer - Dormant Projects (Contd..4), H2 2016
  • Bladder Cancer - Dormant Projects (Contd..5), H2 2016
  • Bladder Cancer - Dormant Projects (Contd..6), H2 2016
  • Bladder Cancer - Dormant Projects (Contd..7), H2 2016
  • Bladder Cancer - Dormant Projects (Contd..8), H2 2016
  • Bladder Cancer - Dormant Projects (Contd..9), H2 2016
  • Bladder Cancer - Discontinued Products, H2 2016

List of Figures

  • Number of Products under Development for Bladder Cancer, H2 2016
  • Number of Products under Development for Bladder Cancer - Comparative Analysis, H2 2016
  • Number of Products under Development by Companies, H2 2016
  • Number of Products under Investigation by Universities/Institutes, H2 2016
  • Comparative Analysis by Late Stage Development, H2 2016
  • Comparative Analysis by Clinical Stage Development, H2 2016
  • Comparative Analysis by Early Stage Products, H2 2016
  • Assessment by Monotherapy Products, H2 2016
  • Assessment by Combination Products, H2 2016
  • Number of Products by Top 10 Targets, H2 2016
  • Number of Products by Stage and Top 10 Targets, H2 2016
  • Number of Products by Top 10 Mechanism of Actions, H2 2016
  • Number of Products by Stage and Top 10 Mechanism of Actions, H2 2016
  • Number of Products by Top 10 Routes of Administration, H2 2016
  • Number of Products by Stage and Top 10 Routes of Administration, H2 2016
  • Number of Products by Top 10 Molecule Types, H2 2016
  • Number of Products by Stage and Top 10 Molecule Types, H2 2016
Back to Top